Skip to primary navigation
Skip to main content
Skip to primary sidebar

The Lp(a) Forum is made possible thanks to support from Amgen, AstraZeneca and Pfizer, who have no influence or control over editorial content. More information is available here »

Join our community
Login

Enter your search

About
Back to Basics
From the Editors
- Expert Commentaries
- Expert Views
Expert Meetings
News
- Congress Reports
- News
Trials
Guidelines
Videos
Slides
Resources

Phase 1 data show sustained Lp(a) reduction with lepodisiran

You are here: Home > Congress Reports

Primary Sidebar

Please login or create a FREE account to view this content

Email Address*

Password*

Only fill in if you are not human

Keep me signed in

Forgot your password?

Educational Partners and Supporters

AstraZeneca has provided a sponsorship grant towards this independent programme.

Editorial Policy

Unless otherwise indicated, opinions expressed in Lp(a) Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of Lp(a) Forum, Co-Chairs, Steering Committee, Editorial Advisory Board, Secretariat or Grantors is accepted for the consequences of any misleading or inaccurate information.

© Copyright 2026 Lp(a) Forum. All rights reserved.

Homepage
Privacy Policy
Governance
Disclaimer Statement
Contact